Search results
Results from the WOW.Com Content Network
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]
Zanzalintinib (also known as XL092) is an oral drug that is undergoing clinical studies. It could potentially be used to treat renal cell carcinoma (RCC). It is being developed by Exelixis. [1] [2] STELLAR-303 is a phase 3, randomized study of zanzalintinib in combination with atezolizumab versus regorafenib in metastatic colorectal cancer. [3]
3 times a day t.i.d., t.d. ter in die: 3 times a day AMA style avoids use of this abbreviation (spell out "3 times a day") tinct. tinctura: tincture t.i.w. 3 times a week mistaken for "twice a week" top. topical TPN total parenteral nutrition tr, tinc., tinct. tinctura: tincture trit. triturate: grind to a powder troch. trochiscus: lozenge tsp
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. [4] [6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. [4]
The drug is expelled via the laser-drilled hole visible on the left side of the tablet. The osmotic-controlled release oral delivery system (OROS) is an advanced controlled release oral drug delivery system in the form of a rigid tablet with a semi-permeable outer membrane and one or more small laser drilled holes in it.
The saying “knowledge is power” applies well in certain situations — like becoming a leader in your field of expertise or knowing the best places to eat (we all have different skills).
It delivers 50% of the dosage as IR MPH and the remaining 50% in 3–4 hours. [188] [189] Jornay PM is a delayed release formulation that is taken at bedtime. An outer polymer coating delays the initial release of the drug until 8 hours after administration, after which an inner coating regulates the rate of drug absorption.
XL-413 is a drug which acts as a selective inhibitor of the enzyme cell division cycle 7-related protein kinase (CDC7). It is being researched for the treatment of some forms of cancer, and also has applications in genetic engineering. [1] [2] [3] [4]